PBE
Price
$95.73Alerts
Change
-$0.09 (-0.09%)
Updated
Nov 17, 04:59 PM (EDT)
Net Assets
436.74M
Intraday BUY SELL Signals
XBI
Price
$145.31Alerts
Change
-$0.57 (-0.39%)
Updated
Nov 17, 04:59 PM (EDT)
Net Assets
10.35B
Intraday BUY SELL Signals
Interact to see
Advertisement

PBE vs XBI

PBE vs XBI Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 21, 2026

Which ETF would AI Choose? Invesco Biotechnology & Genome ETF (PBE) vs. SPDR S&P Biotech ETF (XBI)

Key Takeaways

  • Invesco Biotechnology & Genome ETF (PBE) employs a multi-factor Intellidex strategy selecting approximately 30 holdings with quarterly rebalancing, while SPDR S&P Biotech ETF (XBI) uses an equal-weighted approach across roughly 165 holdings for broader exposure.
  • PBE concentrates on companies benefiting from biotechnology and genetic engineering advances with top positions often exceeding 5% weight, whereas XBI distributes risk more evenly with individual holdings typically under 3%.
  • XBI offers a lower expense ratio of 0.35% compared to PBE’s 0.59%, potentially improving net returns for cost-sensitive investors over time.
  • Both ETFs provide targeted U.S. biotechnology sector exposure but differ in risk profiles: PBE’s concentrated, rules-based selection may amplify volatility from key holdings, while XBI’s equal weighting emphasizes small- and mid-cap names.
  • Structural differences position PBE as a thematic, momentum-driven vehicle and XBI as a diversified industry benchmark tracker within the same healthcare subsector.

Introduction

Investors seeking biotechnology exposure often compare Invesco Biotechnology & Genome ETF (PBE) and SPDR S&P Biotech ETF (XBI) because both target the same dynamic sector yet follow distinct methodologies. These funds do not compete directly but offer alternative strategies for capturing growth from drug development, genomics, and related innovations. PBE applies quantitative screens for momentum and quality, while XBI delivers modified equal-weighted representation of the broader biotechnology industry. The comparison helps clarify trade-offs in concentration, cost, and diversification for portfolio construction in the current environment of evolving healthcare innovation and regulatory scrutiny.

Invesco Biotechnology & Genome ETF (PBE) Overview

Invesco Biotechnology & Genome ETF (PBE) seeks to track the Dynamic Biotech & Genome Intellidex Index, which evaluates U.S. biotechnology and genome companies using criteria including price momentum, earnings momentum, quality, management action, and value. The fund maintains approximately 30 to 32 holdings and reconstitutes quarterly. Top positions as of recent data include Illumina Inc. (ILMN), Natera Inc. (NTRA), Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD), and Amgen Inc. (AMGN), each typically weighted between 4% and 6%. The portfolio is nearly 100% allocated to healthcare, primarily biotechnology. Its expense ratio stands at 0.59%. The strategy represents a rules-based, non-diversified approach designed for capital appreciation through multi-factor selection rather than pure market-cap weighting.

SPDR S&P Biotech ETF (XBI) Overview

SPDR S&P Biotech ETF (XBI) aims to track the S&P Biotechnology Select Industry Index, which captures the biotechnology segment of the S&P Total Market Index through modified equal weighting. The fund holds approximately 160 to 165 securities and rebalances quarterly. Individual holdings generally range from 1% to 2.5%, with recent top names including Moderna Inc. (MRNA), Natera Inc. (NTRA), Twist Bioscience Corp. (TWST), and Amgen Inc. (AMGN). Exposure remains overwhelmingly in healthcare biotechnology. The expense ratio is 0.35%. This passive structure provides broad industry representation with reduced single-name concentration, emphasizing smaller-capitalization companies alongside larger peers.

Industry and Thematic Backdrop

The biotechnology sector continues to benefit from advances in gene editing, personalized medicine, and novel therapeutics, supported by ongoing research pipelines and potential regulatory approvals. Macroeconomic factors such as interest rate expectations influence capital availability for research-intensive firms, while policy developments around drug pricing and intellectual property remain key variables. Capital flows into healthcare innovation have shown resilience across recent market cycles, though sector volatility persists due to clinical trial outcomes and competitive pressures. Both ETFs operate within this environment, where scientific breakthroughs can drive long-term growth alongside risks from development failures and reimbursement challenges.

Performance and Positioning Comparison

Over recent weeks and months, the funds have reflected broader biotechnology sector rotation driven by earnings reports from leading companies and shifting sentiment around innovation pipelines. PBE’s concentrated holdings can lead to sharper moves tied to specific catalysts in its top names, while XBI’s equal weighting tends to moderate extreme swings through broader participation across market-capitalization tiers. In recent market cycles, XBI’s lower cost structure and diversified profile have positioned it for steadier exposure during periods of sector-wide momentum, whereas PBE’s multi-factor methodology may capture outperformance from selected high-momentum securities. Relative positioning highlights trade-offs between targeted selection and comprehensive industry coverage amid evolving macroeconomic conditions.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into funds like Invesco Biotechnology & Genome ETF (PBE) or SPDR S&P Biotech ETF (XBI) may find the platform useful for refining their research process.

Tickeron AI Verdict

Based on structural strength, cost efficiency, and diversification profile, Tickeron’s AI would currently assign a higher probability of favor to SPDR S&P Biotech ETF (XBI). Its lower expense ratio, broader holding count, and equal-weighted methodology provide more consistent sector representation with reduced concentration risk compared to the more selective, higher-cost approach of Invesco Biotechnology & Genome ETF (PBE). Trend consistency and risk exposure metrics further support this probabilistic assessment within the biotechnology thematic space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
PBE vs. XBI commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBE is a Hold and XBI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for PBE with price predictions
Nov 16, 2026

PBE's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for PBE moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 22 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBE as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for PBE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

PBE moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for PBE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in 259 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

PBE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 218 of 254 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

A.I.Advisor
a Summary for XBI with price predictions
Nov 16, 2026

XBI in downward trend: price dove below 50-day moving average on November 12, 2026

XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 50 of 53 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 77 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 45 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

TECHNICAL ANALYSIS
Technical Analysis
PBEXBI
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
84%
Bullish Trend 9 days ago
90%
Declines
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement

PBE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBE has been loosely correlated with NTLA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PBE jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBE
1D Price
Change %
PBE100%
-2.10%
NTLA - PBE
64%
Loosely correlated
+1.65%
RGNX - PBE
61%
Loosely correlated
-4.19%
AVXL - PBE
52%
Loosely correlated
-12.42%
PRTA - PBE
50%
Loosely correlated
-2.33%
PGEN - PBE
50%
Loosely correlated
-5.29%
More

XBI and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBI
1D Price
Change %
XBI100%
-3.10%
RCUS - XBI
60%
Loosely correlated
-3.27%
VYGR - XBI
59%
Loosely correlated
-5.78%
LYEL - XBI
57%
Loosely correlated
+2.45%
LGND - XBI
56%
Loosely correlated
-2.29%
MGNX - XBI
55%
Loosely correlated
-1.36%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRMD4.820.16
+3.43%
CorMedix
DCI85.20-1.50
-1.73%
Donaldson Company
DRVN10.97-0.36
-3.18%
Driven Brands Holdings
DXF0.25-0.01
-5.11%
Eason Technology Limited
RSSS1.89-0.12
-5.97%
Research Solutions